Literature DB >> 22969838

Modulation of estrogenic action in clear cell carcinoma of the ovary (Review).

Yasuhito Tanase1, Yoshihiko Yamada, Hiroshi Shigetomi, Hirotaka Kajihara, Akira Oonogi, Yoriko Yoshizawa, Naoto Furukawa, Shoji Haruta, Shozo Yoshida, Toshiyuki Sado, Hidekazu Oi, Hiroshi Kobayashi.   

Abstract

Two histologic types, clear cell carcinoma (CCC) and endometrioid adenocarcinoma (EAC), are the common histology in ovarian cancer patients who have associated endometriosis. However, both tumor types have distinct clinicopathological characteristics and molecular phenotypes. EAC is predominantly positive for estrogen receptor (ER), but CCC specifically exhibits lower ER expression. This study reviews the current understanding of the role of the ER information in the pathogenesis of CCC, as well as the English language literature for biochemical studies on ER expression and estrogenic action in CCC. The iron-mediated oxidative stress occurs due to repeated hemorrhage in endometriosis, then this compound oxidatively modifies genomic DNA and, subsequently, ER depletion may be observed. There are a number of factors that interfere with ER expression and estrogen activity, which include DNA methylation of the promoter region, histone deacetylation, heme and iron binding, chromatin remodeling and ubiquitin ligase activity. Loss of estrogen function may be a turning point in CCC progression and aggressiveness.

Entities:  

Year:  2011        PMID: 22969838      PMCID: PMC3438704          DOI: 10.3892/etm.2011.376

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  39 in total

1.  Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma.

Authors:  Akira Tsuchiya; Michiie Sakamoto; Jun Yasuda; Makoto Chuma; Tsutomu Ohta; Misao Ohki; Toshiharu Yasugi; Yuji Taketani; Setsuo Hirohashi
Journal:  Am J Pathol       Date:  2003-12       Impact factor: 4.307

2.  Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer.

Authors:  Daniela M Dinulescu; Tan A Ince; Bradley J Quade; Sarah A Shafer; Denise Crowley; Tyler Jacks
Journal:  Nat Med       Date:  2004-12-26       Impact factor: 53.440

3.  The metastasis-associated gene MTA1 is upregulated in advanced ovarian cancer, represses ERbeta, and enhances expression of oncogenic cytokine GRO.

Authors:  Christine Dannenmann; Naim Shabani; Klaus Friese; Udo Jeschke; Ioannis Mylonas; Ansgar Brüning
Journal:  Cancer Biol Ther       Date:  2008-09-11       Impact factor: 4.742

4.  Activation of ATP-binding cassette transporter A1 transcription by chromatin remodeling complex.

Authors:  Jarkko Huuskonen; Meeta Vishnu; Phoebe E Fielding; Christopher J Fielding
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-03-17       Impact factor: 8.311

5.  Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.

Authors:  Siân Jones; Tian-Li Wang; Ie-Ming Shih; Tsui-Lien Mao; Kentaro Nakayama; Richard Roden; Ruth Glas; Dennis Slamon; Luis A Diaz; Bert Vogelstein; Kenneth W Kinzler; Victor E Velculescu; Nickolas Papadopoulos
Journal:  Science       Date:  2010-09-08       Impact factor: 47.728

6.  Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells.

Authors:  Y L Ottaviano; J P Issa; F F Parl; H S Smith; S B Baylin; N E Davidson
Journal:  Cancer Res       Date:  1994-05-15       Impact factor: 12.701

Review 7.  The role of hepatocyte nuclear factor-1beta in the pathogenesis of clear cell carcinoma of the ovary.

Authors:  Hiroshi Kobayashi; Yoshihiko Yamada; Seiji Kanayama; Naoto Furukawa; Taketoshi Noguchi; Shoji Haruta; Shozo Yoshida; Mariko Sakata; Toshiyuki Sado; Hidekazu Oi
Journal:  Int J Gynecol Cancer       Date:  2009-04       Impact factor: 3.437

Review 8.  Ovarian cancer in endometriosis: molecular biology, pathology, and clinical management.

Authors:  Masaki Mandai; Ken Yamaguchi; Noriomi Matsumura; Tsukasa Baba; Ikuo Konishi
Journal:  Int J Clin Oncol       Date:  2009-10-25       Impact factor: 3.402

9.  Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes.

Authors:  K Yamaguchi; M Mandai; T Oura; N Matsumura; J Hamanishi; T Baba; S Matsui; S K Murphy; I Konishi
Journal:  Oncogene       Date:  2010-01-11       Impact factor: 9.867

10.  Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging.

Authors:  M Takano; Y Kikuchi; N Yaegashi; K Kuzuya; M Ueki; H Tsuda; M Suzuki; J Kigawa; S Takeuchi; H Tsuda; T Moriya; T Sugiyama
Journal:  Br J Cancer       Date:  2006-05-22       Impact factor: 7.640

View more
  8 in total

1.  Checkpoint kinase 1 inhibitors as targeted molecular agents for clear cell carcinoma of the ovary.

Authors:  Hiroshi Kobayashi; Hiroshi Shigetomi; Chiharu Yoshimoto
Journal:  Oncol Lett       Date:  2015-05-26       Impact factor: 2.967

Review 2.  Endometriosis: pathogenesis and treatment.

Authors:  Paolo Vercellini; Paola Viganò; Edgardo Somigliana; Luigi Fedele
Journal:  Nat Rev Endocrinol       Date:  2013-12-24       Impact factor: 43.330

3.  Toward an understanding of the pathophysiology of clear cell carcinoma of the ovary (Review).

Authors:  Chiharu Uekuri; Hiroshi Shigetomi; Sumire Ono; Yoshikazu Sasaki; Miyuki Matsuura; Hiroshi Kobayashi
Journal:  Oncol Lett       Date:  2013-08-28       Impact factor: 2.967

4.  Clinical Significance of Tissue Factor Pathway Inhibitor 2, a Serum Biomarker Candidate for Ovarian Clear Cell Carcinoma.

Authors:  Noriaki Arakawa; Hiroshi Kobayashi; Naohiro Yonemoto; Yusuke Masuishi; Yoko Ino; Hiroshi Shigetomi; Naoto Furukawa; Norihisa Ohtake; Yohei Miyagi; Fumiki Hirahara; Hisashi Hirano; Etsuko Miyagi
Journal:  PLoS One       Date:  2016-10-31       Impact factor: 3.240

5.  Ovarian Clear Cell Carcinoma Sub-Typing by ARID1A Expression.

Authors:  Jae Yoon Choi; Hyun Ho Han; Young Tae Kim; Joo Hyun Lee; Baek Gil Kim; Suki Kang; Nam Hoon Cho
Journal:  Yonsei Med J       Date:  2017-01       Impact factor: 2.759

6.  Developmental Toxicant Exposure Is Associated with Transgenerational Adenomyosis in a Murine Model.

Authors:  Kaylon L Bruner-Tran; Antoni J Duleba; Hugh S Taylor; Kevin G Osteen
Journal:  Biol Reprod       Date:  2016-08-17       Impact factor: 4.285

7.  Endometriosis and ovarian cancer: Their association and relationship.

Authors:  Ernesto Bas-Esteve; María Pérez-Arguedas; Gonzalo Ariel Guarda-Muratori; Maribel Acién; Pedro Acién
Journal:  Eur J Obstet Gynecol Reprod Biol X       Date:  2019-05-22

8.  Endometriosis-associated ovarian cancer: a review of pathogenesis.

Authors:  Michael J Worley; William R Welch; Ross S Berkowitz; Shu-Wing Ng
Journal:  Int J Mol Sci       Date:  2013-03-06       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.